We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+34.92%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.07B
AUM Growth
+$237M
Cap. Flow
+$422M
Cap. Flow %
39.55%
Top 10 Hldgs %
35.09%
Holding
191
New
51
Increased
37
Reduced
12
Closed
55

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$32.6M
2
XHB icon
State Street SPDR S&P Homebuilders ETF
XHB
+$16.3M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$13.4M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$12.7M
5
ALPN
Alpine Immune Sciences Inc
ALPN
+$6.77M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$10.1M
2
RCKT icon
Rocket Pharmaceuticals
RCKT
+$9.16M
3
SLRN
ACELYRIN
SLRN
+$7.92M
4
PCVX icon
Vaxcyte
PCVX
+$7.26M
5
GPCR icon
Structure Therapeutics
GPCR
+$7.07M

Sector Composition

Rank Sector Weight
1 Healthcare 31.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDX icon
176
PUT
Syndax Pharmaceuticals
SNDX
$1.69B
– –
-7,500
Closed -$10.9M
SPY icon
177
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
– –
-1,500
Closed -$64.1M
STOK icon
178
CALL
Stoke Therapeutics
STOK
$1.8B
– –
-500
Closed -$197K
SWTX
179
DELISTED
SpringWorks Therapeutics
SWTX
– –
-178,360
Closed -$4.12M
TERN
180
CALL
DELISTED
Terns Pharmaceuticals
TERN
– –
-2,000
Closed -$1.01M
TGTX icon
181
TG Therapeutics
TGTX
$7.96B
– –
-32,547
Closed -$272K
VERV
182
CALL
DELISTED
Verve Therapeutics
VERV
– –
-2,000
Closed -$2.65M
VTGN icon
183
VistaGen Therapeutics
VTGN
$9.89M
– –
-229,100
Closed -$1.2M
VTYX
184
PUT
DELISTED
Ventyx Biosciences
VTYX
– –
-1,233
Closed -$4.28M
MORF
185
CALL
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-14
Closed -$32.1K
MORF
186
PUT
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-129
Closed -$296K
CBAY
187
CALL
DELISTED
Cymabay Therapeutics
CBAY
– –
-2,230
Closed -$3.32M
CBAY
188
DELISTED
Cymabay Therapeutics
CBAY
– –
-104,300
Closed -$1.56M
CBAY
189
PUT
DELISTED
Cymabay Therapeutics
CBAY
– –
-816
Closed -$1.22M
PHXM
190
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
– –
-301
Closed -$1.56K
AMAM
191
CALL
DELISTED
Ambrx Biopharma Inc
AMAM
– –
-4,932
Closed -$5.67M
4 5 6 7
8

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Ikarian Capital held 191 positions worth $1.07B, up 28% from $831M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Ikarian Capital deployed $422M of net new capital in Q4 2023, opening 51 new positions and adding to 37 existing holdings. Its largest new stake was argenx: 70,000 shares worth $26.5M.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 32% a quarter earlier.

On the sell side, the largest reduction was Rocket Pharmaceuticals, an estimated $9.16M trimmed.

  • Ikarian Capital's largest Q4 2023 buy was argenx: 70,000 shares worth $26.5M.
  • Ikarian Capital added most to Disc Medicine in Q4 2023, an estimated $2.67M increase.
  • Ikarian Capital's biggest Q4 2023 reduction was Rocket Pharmaceuticals, cutting an estimated $9.16M.
  • Ikarian Capital fully exited Akero Therapeutics in Q4 2023, selling an estimated $10.1M.
  • Ikarian Capital's ten largest holdings make up 35% of its $1.07B portfolio in Q4 2023.
  • Ikarian Capital opened 51 new positions and closed 55 in Q4 2023.
  • Ikarian Capital's portfolio value rose 28% quarter-over-quarter to $1.07B.

Based on Ikarian Capital's 13F filing for Q4 2023, filed 14 Feb 2024.